肿瘤细胞治疗研究
英文原题：Counting the CHIPs: The High-Stakes Role of Clonal Hematopoiesis in Multiple Myeloma.
意义未明的克隆性造血（CHIP）是骨髓中体细胞突变的造血干细胞（HSCs）的克隆性扩增。
意义未明的克隆性造血（CHIP）是骨髓中体细胞突变的造血干细胞（HSCs）的克隆性扩增。CHIP突变在多发性骨髓瘤（MM）中相对常见，并已被确定为生存结局较差的潜在生物标志物。MM是一种血液系统恶性肿瘤，尽管治疗取得了进展，但对许多患者而言仍具有侵袭性且无法治愈。CHIP突变对MM治疗结局的潜在影响已成为近期多项研究的主题，然而CHIP对治疗和疾病进展产生负面影响的幅度和方式仍有待完全阐明。证据表明，CHIP突变可能导致生存期和治疗耐受性较差，并导致更大的治疗毒性和相关的衰弱。在这篇综述中，我们综合并讨论了现有文献，以提供对CHIP在改变MM微环境中复杂作用的最新认识，及其对标准MM治疗、自体干细胞移植（ASCT）和B细胞成熟抗原（BCMA）靶向治疗/CAR-T的影响，以及免疫调节药物（IMiD）维持治疗在临床结局中的重要作用。
Clonal hematopoiesis of indeterminate potential (CHIP) is the clonal expansion of somatically mutated hematopoietic stem cells (HSCs) in the bone marrow. CHIP mutations are relatively common in multiple myeloma (MM) and have been identified as potential biomarkers for poorer survival outcomes. MM is a hematological malignancy that, despite treatment advances, remains aggressive and incurable for many patients. The potential impact of CHIP mutations on the outcomes of MM treatments has been the topic of several recent studies, yet both the magnitude and the modality by which CHIP exerts its negative effects on treatment and disease progression remain to be fully elucidated. Evidence suggests that CHIP mutations may contribute to inferior survival and treatment tolerances, as well as contribute to greater treatment toxicity and related frailty. In this review, we synthesize and discuss the available literature to provide an updated understanding of the complex role that CHIP plays in altering the MM microenvironment, and the resulting impact on standard MM treatments, autologous stem cell transplant (ASCT) and B-cell maturation antigen (BCMA)-targeted therapy/CAR-T, and the important role of immunomodulatory drug (IMiD) maintenance therapy in clinical outcomes.
MEMBER ACCOUNT
登录成功会直接打开下一页。
